Humacyte Shares Surge 38% on FDA Approval of Symvess

Dow Jones12-20 19:56

By Denny Jacob

Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults.

Shares were trading around $4.81. The stock is up 22% on the year.

The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible.

Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 20, 2024 06:56 ET (11:56 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492411414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492411414","market":"us","top_or_hot":-1,"title":"Humacyte Shares Surge 38% on FDA Approval of Symvess","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<p>\n  Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults. \n</p>\n<p>\n  Shares were trading around $4.81. The stock is up 22% on the year. \n</p>\n<p>\n  The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible. \n</p>\n<p>\n  Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte. \n</p>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 06:56 ET (11:56 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte Shares Surge 38% on FDA Approval of Symvess</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte Shares Surge 38% on FDA Approval of Symvess\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 19:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n  Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults. \n\n\n  Shares were trading around...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUMA","symbol_name":"Humacyte, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492411414","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492411414","pubTimestamp":1734695760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults.Shares were trading around $4.81. The stock is up 22% on the year.The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible.Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUMA":"Humacyte, Inc.","BK4139":"生物科技","BK4563":"昨日强势股"},"translate_title":"FDA批准Symvess后Humacyte股价飙升38%","themeId":"2fa1cf6b255f3c244a082df08bbda9a2","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":0.9},"content_text":"By Denny Jacob \n\n\n  Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults. \n\n\n  Shares were trading around $4.81. The stock is up 22% on the year. \n\n\n  The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible. \n\n\n  Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte. \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 06:56 ET (11:56 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492411414"}